RBC Capital Mkts initiated coverage on Ocular Therapeutix with a new price target
$OCUL
Biotechnology: Pharmaceutical Preparations
Health Care
RBC Capital Mkts initiated coverage of Ocular Therapeutix with a rating of Outperform and set a new price target of $17.00